- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03062020
New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women
The QUIPP tool integrates information of obstetrical history, quantitative fetal fibronectin (qfFN) and cervical length to predict the risk of sPTB in asymptomatic high-risk women.
The aim of this study is to evaluate the QUIPP tool in our setting in order to optimize the management of women at high risk for sPTB and to validate in a randomized clinical trial, whether the use of QUIPP improves efficiently the management of our asymptomatic high-risk women when it is compared with the current clinical management.
Design: Randomized controlled trial. Inclusion criteria: Asymptomatic singleton pregnancies 18,0-22,6 weeks at high-risk for sPTB. Sample size: According to a non-inferiority analysis, 129 pregnant women will be needed for each arm.
Methodology: Patient selection and who consent to participate in the study will be randomized into two arms: a) Intervention group: QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit. b) Control group: Women will be managed according to current clinical practice.
Main Outcome: sPTB <34,0 and <37,0 weeks of gestation. Secondary Outcomes: Pregnancy outcomes and a neonatal composite morbidity. Expected Results: Perinatal outcomes are similar in the intervention and control group although the intervention group using the QUIPP tool required less medical resources.
Study Overview
Detailed Description
Preterm birth (PTB) is a leading cause of perinatal morbidity and mortality. Women at high-risk of preterm birth are those with a previous spontaneous preterm birth (sPTB) or preterm premature rupture of membranes before 35 weeks of gestation, uterine malformation, surgery on uterine cervix or a short cervical length; these women have a global risk of PTB about 30% but still 75%-85% of these women will deliver at term without any intervention.
The availability of a specialized Preterm Birth Prevention Clinic (PBPC) is relevant for the management of these high-risk pregnant women and it results in a reduction in the risk of recurrent sPTB, pregnancy prolongation and a reduction in the rate of major neonatal morbidity. However, it implies higher outpatient care costs as well as trained personnel and intensive follow-up management even for those women not destined to deliver preterm QUIPP is a free smartphone application that integrates the obstetrical history of high-risk women, the cervical length and the value of quantitative fetal fibronectin to predict the risk of preterm birth. QUIPP will determinate the risk of preterm birth in these high-risk women.
Patients will be randomized in two groups: Intervention group (QUIPP tool arm): QUIPP tool is applied and patients with a high-risk result will be follow-up in a high-risk unit (PBPC) and patients with a low-risk value will be managed in a low-risk unit. Control group (no QUIPP tool arm): current management in a PBPC will be applied.
The use of QUIPP will allow determining which asymptomatic pregnancies with risk factors for sPTB will deliver preterm. Furthermore, we expect to provide the non-specialized clinician with an objective, useful, accurate and efficient tool to manage these women with same pregnancy and neonatal outcomes and using less resource.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Núria Lorente, M.D
- Phone Number: +34932532100
- Email: nlorente@sjdhospitalbarcelona.org
Study Contact Backup
- Name: Montse Palacio, M.D, Ph.D
- Phone Number: 9904 +3493 227 9946
- Email: MPALACIO@clinic.cat
Study Locations
-
-
-
Barcelona, Spain, 08028
- Recruiting
- Hospital Clínic Barcelona ( Maternitat)
-
Contact:
- Montse Palacio, M.D, Ph.D
- Phone Number: 9904 +34932279946
- Email: MPALACIO@clinic.cat
-
Sub-Investigator:
- Teresa Cobo, M.D, Ph. D
-
Sub-Investigator:
- Federico Migliorelli, M.D
-
Sub-Investigator:
- Núria Baños, M.D
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spain, 08950
- Recruiting
- Hospital Sant Joan de Déu
-
Contact:
- Núria Lorente, M.D
- Phone Number: +34932532100
- Email: nlorente@sjdbarcelonahospital.org
-
Principal Investigator:
- Núria Lorente, M.D
-
Sub-Investigator:
- Sílvia Ferrero, M.D, Ph.D
-
Sub-Investigator:
- Rosalia Pascal, Resident
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Asymptomatic singleton pregnancies, with at least one of the following: Previous spontaneous preterm delivery or a preterm premature rupture of membranes ≤ 346 weeks of gestation, Previous spontaneous second trimester miscarriage, Previous surgery on uterine cervix, Incidental finding of cervical length less than 25mm, Uterine malformations.
- Able to sign informed consent form.
Exclusion Criteria:
- Multiple pregnancies.
- Congenital, chromosomal abnormalities or stillbirth in current pregnancy.
- No patient consent to participate in the study
- Women with an obstetrical history of iatrogenic preterm birth indicated for maternal or fetal conditions.
- Symptomatic high-risk women or preterm prelabor rupture of membranes in current pregnancy.
- Pregnant women with an indication of prophylactic cervical cerclage due to her own obstetrical history.
- Pregnant women with a short cervix detected by ultrasound and with an indication to perform a cervical cerclage, prior to study inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group: QUIPP tool arm
In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
|
Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given.
Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
|
No Intervention: Control group: no QUIPP tool arm
Women will be managed according to current clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spontaneous preterm birth before 34.0 and 37.0 weeks of gestation
Time Frame: 3.5 years
|
Delivery < 34.0 and <37.0 weeks of gestation ( Yes/No )
|
3.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gestational age at delivery
Time Frame: 3,5 years
|
Weeks and days at the moment of delivery
|
3,5 years
|
Hospital admission due to sPTB or PPROM
Time Frame: 3.5 years
|
Number of hospital admission due to a spontaneous preterm labor or a preterm premature rupture of membranes
|
3.5 years
|
Emergency department visits due to uterine contractions
Time Frame: 3.5 years
|
Number of emergency department visits
|
3.5 years
|
Clinical chorioamnionitis
Time Frame: 3.5 years
|
Fever ( >37.8 ºC) and maternal tachycardia ( >100 beats per minute) and /or fetal tachycardia ( >160 beats per minute) and/or maternal leukocytosis ( >15000 leukocites/mm3) and/or uterine contractions and/or malodorous leukorrhea
|
3.5 years
|
Maternal mortality
Time Frame: 3.5 years
|
Maternal death (Yes/No)
|
3.5 years
|
5 min APGAR score <7
Time Frame: 3.5 years
|
APGAR test less than 7 at the 5 minuts after birth
|
3.5 years
|
umbilical artery pH at delivery <7.1
Time Frame: 3.5 years
|
pH artery value less than 7.1
|
3.5 years
|
NCIU admission
Time Frame: 3.5 years
|
Admission in a neonatal intensive care unit ( Yes/No)
|
3.5 years
|
Need for respiratory support
Time Frame: 3.5 years
|
Administration of respiratory support during the NCIU stay.
|
3.5 years
|
Respiratory distress syndrome
Time Frame: 3.5 years
|
Breathing disorder ( Yes /No)
|
3.5 years
|
Intraventricular haemorrhage
Time Frame: 3.5 years
|
Severe intraventricular haemorrhage grade III/IV
|
3.5 years
|
Necrotizing enterocolitis
Time Frame: 3.5 years
|
Intestinal necrosis in the newborn ( Yes/No)
|
3.5 years
|
Neonatal sepsis
Time Frame: 3.5 years
|
Blood infection of the newborn (Yes/No)
|
3.5 years
|
Neonatal mortality
Time Frame: 3.5 years
|
neonatal death
|
3.5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Núria Lorente, M.D, BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine | Hospital Clínic - Hospital Sant Joan de Déu
Publications and helpful links
General Publications
- Kurtzman J, Chandiramani M, Briley A, Poston L, Das A, Shennan A. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery. Am J Obstet Gynecol. 2009 Mar;200(3):263.e1-6. doi: 10.1016/j.ajog.2009.01.018.
- Abbott DS, Hezelgrave NL, Seed PT, Norman JE, David AL, Bennett PR, Girling JC, Chandirimani M, Stock SJ, Carter J, Cate R, Kurtzman J, Tribe RM, Shennan AH. Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk. Obstet Gynecol. 2015 May;125(5):1168-1176. doi: 10.1097/AOG.0000000000000754.
- Kuhrt K, Smout E, Hezelgrave N, Seed PT, Carter J, Shennan AH. Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women. Ultrasound Obstet Gynecol. 2016 Jan;47(1):104-9. doi: 10.1002/uog.14865.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCB/2016/0552
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PreTerm Birth
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Thomas Jefferson UniversityCompleted
-
Chelsea and Westminster NHS Foundation TrustSPD Development Company Limited; Borne CharityRecruitingPreterm Birth | Preterm Labor | Preterm Birth Complication | Preterm Premature Rupture of Membrane | Preterm PregnancyUnited Kingdom
-
Cairo UniversityCompleted
-
University of OklahomaCompletedPreTerm Birth | PreTerm NeonateUnited States
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Federico II UniversityRecruiting
-
University of OxfordShoklo Malaria Research UnitCompleted
-
Eunice Kennedy Shriver National Institute of Child...CompletedPregnancy | Preterm Birth | Preterm LaborUnited States
-
University Hospital Inselspital, BerneAmniSure International LLCCompletedPreterm Birth | Preterm LabourSwitzerland